Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
EAST RUTHERFORD, N.J., Nov. 01, 2016 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that third quarter 2016 financial results will be released on Friday, November 4, 2016 before the market opens.
The Company will host a conference call to discuss the financial results.
| Third Quarter 2016 Earnings Conference Call | ||
| When: | Friday, November 4, 2016 at 8:30 a.m. Eastern Time | |
| Dial-in: | 1-888-262-8770 for U.S. | |
| 1-913-312-1227 for International | ||
| Passcode: 2914880 | ||
| Dial-in Replay: | 1-888-203-1112 for U.S. | |
| 1-719-457-0820 for International | ||
| Passcode: 2914880 | ||
| Available through Friday, November 11, 2016 | ||
| Webcast: | www.cambrex.com | |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura Investor Relations Associate Tel: 201-804-3037 Email: [email protected]
